<!–*/ */ /*–>*/ (RTTNews) – Today’s Daily Dose brings you news about Akcea’s promising trial results of antisense drug AKCEA-APOCIII-LRx, Applied Genetic’s upcoming event, the near-term catalyst of Baudax Bio and Sierra Oncology’s reverse stock split. Shares of Akcea Therapeutics Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc., and Ionis Pharmaceuticals Inc. (IONS) rose more than 10% on Wednesday, following positive topline results from the phase II study of the antisense drug AKCEA-APOCIII-LRx in the treatment of patients with hypertriglyceridemia who are at risk for or have established cardiovascular disease (CVD). The study met the primary endpoint of significant triglyceride lowering and multiple secondary endpoints with a favorable safety and tolerability profile. According to the Company, at the highest, once-monthly dose of 50 mg, more than 90% of patients achieved serum triglycerides of less than or equal to 150 mg/dL, compared to less than 5% of patients in the placebo group. The mean triglyceride level of patients at baseline was 285 mg/dL. Applied Genetic Technologies Corp. (AGTC) is all set to anno...